367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents

BACKGROUND: Increased community COVID-19 cases prompted the clinical evaluation of an mRNA-1273 booster dose (BD) in TeenCOVE adolescent participants (12-17 years) who received a 2-dose mRNA-1273 primary series. At ≥5 months after dose 2 (coinciding with the omicron wave peak in Jan 2022), TeenCOVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Figueroa, Amparo, Ali, Kashif, Berman, Gary, Zhou, Honghong, Deng, Weiping, Patel, Monali, Girard, Bethany, Yeakey, Anne, Slobod, Karen, Priddy, Frances, Miller, Jacqueline, Das, Rituparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676862/
http://dx.doi.org/10.1093/ofid/ofad500.437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676862/
http://dx.doi.org/10.1093/ofid/ofad500.437

Ejemplares similares